Nicole Hamblin leads a team of medicinal, synthetic, and computational chemists, and provides strategic oversight on integrated drug discovery projects. In 20 years with GlaxoSmithKline, her many accomplishments include leadership of a multi-asset PI3Kδ Inhibitor portfolio from hit ID into Phase II clinical trials, culminating in 3 candidate compounds and successful progression of inhaled asset nemiralisib into Phase IIa clinical trials for respiratory indications. She is co-inventor on more than 25 patents, covering 8 clinical candidates and has co-authored 19 peer reviewed publications.
In 2014, Dr. Hamblin won the Royal Society of Chemistry Capps Green Zomaya Award for Medicinal Chemistry for her work on PI3Kδ and was appointed a Fellow of the Royal Society of Chemistry in 2017. She holds a first-class degree and a PhD in chemistry, both from Oxford University.
- Translation of inhaled drug optimization strategies into clinical pharmacokinetics and pharmacodynamics using GSK2292767A, a novel inhaled PI3Kδ inhibitor
- A multicentre, randomized, double-blind, placebo-controlled, crossover study to investigate the efficacy, safety, tolerability, and pharmacokinetics of repeat doses of inhaled nemiralisib in adults with persistent, uncontrolled asthma